<DOC>
	<DOCNO>NCT01989546</DOCNO>
	<brief_summary>Background : - The poly ( ADP-ribose ) polymerase ( PARP ) family enzymes critical maintain genomic stability regulate variety DNA damage repair mechanism . - BMN 673 PARP inhibitor great vitro activity PARP inhibitor currently development . BMN 673 show cause single-agent synthetic lethality BRCA1/2- PTEN-deficient cell line , potent antitumor activity animal model tumor harbor mutation DNA repair pathway . - BMN 673 show promising single-agent activity patient advance ovarian breast cancer harbor deleterious BRCA mutation . - This pilot study evaluate pharmacodynamic effect BMN 673 DNA damage apoptosis marker tumor biopsy tissue . Primary Objective : -Determine pharmacodynamic effect BMN 673 tumor biopsy patient advanced ovarian , breast , solid tumor deleterious BRCA mutation . Secondary Objectives : - Determine response rate ( CR + PR ) treatment BMN 673 patient advanced ovarian primary peritoneal carcinoma deleterious BRCA mutation . - Determine response rate ( CR + PR ) treatment BMN 673 patient advance breast carcinoma deleterious BRCA mutation . - Determine response rate ( CR + PR ) treatment BMN 673 patient advance solid tumor ( breast ovarian ) deleterious BRCA mutation . Eligibility : - Adult patient document deleterious BRCA 1 2 mutation histologically confirm ovarian , primary peritoneal , breast , prostate , pancreas , gastric solid tumor whose disease progress follow least one standard therapy acceptable standard treatment option . - No major surgery , radiation , chemotherapy within 4 week prior study enrollment , recover toxicity prior therapy least eligibility level . - Age great equal 18 year age ; ECOG performance status less equal 2 - Adequate organ function . - Willingness undergo tumor biopsy . Study Design : - BMN 673 administer orally day 28-day cycle . - Dosing establish recommended Phase II dose 1000 mcg/day day 28 day . - We plan accrue total 12 evaluable patient per cohort total 36 patient . To allow patient evaluable , accrual ceiling 42 patient . - Tumor biopsy mandatory baseline ( pre-dose ) , approximately 3-6 hour post BMN 673 day 8 . An optional tumor biopsy may also collect time disease progression . SCHEMA - BMN 673 administer orally day 28-day cycle - Tumor biopsy perform baseline ( pre-treatment ) 3-6 hr post dose cycle 1 day 8 . An optional tumor biopsy may also collect time disease progression . Tumor biopsy evaluate PAR level , DNA damage response marker &gt; =H2AX , cleave caspase 3 , ERCC1 , pNbs1 , XPF , RAD51 , pT1989ATR , , indicator ATR/ATM activation , chk1 chk2 - Blood sample CTC analysis collect baseline ( pre-treatment ) , cycle 1 day 1 ( 3-6 hour post dose ) , cycle 1 day 8 ( 3-6 hour post dose ) , cycle 2 day 1 ( 3-6 hour post dose ) - Blood sample PK analysis collect cycle 1 day 1 pre-dose 0.5 , 1 , 2 , 3 , 4 , 6,8 , 24 hour post-dose , cycle 1 day 8 ( 3-6 hour post dose ) , cycle 2 day 1 predose 3-6 hour post dose .</brief_summary>
	<brief_title>Pilot Trial BMN 673 , Oral PARP Inhibitor , Patients With Advanced Solid Tumors Deleterious BRCA Mutations</brief_title>
	<detailed_description>Background : - The poly ( ADP-ribose ) polymerase ( PARP ) family enzymes critical maintain genomic stability regulate variety DNA damage repair mechanism . - BMN 673 PARP inhibitor great vitro activity PARP inhibitor currently development . BMN 673 show cause single-agent synthetic lethality BRCA1/2- PTEN-deficient cell line , potent antitumor activity animal model tumor harbor mutation DNA repair pathway . - BMN 673 show promising single-agent activity patient advance ovarian breast cancer harbor deleterious BRCA mutation . - This pilot study evaluate pharmacodynamic effect BMN 673 DNA damage apoptosis marker tumor biopsy tissue . Primary Objective : -Determine pharmacodynamic effect BMN 673 tumor biopsy patient advanced ovarian , breast , solid tumor deleterious BRCA mutation . Secondary Objectives : - Determine response rate ( CR + PR ) treatment BMN 673 patient advanced ovarian primary peritoneal carcinoma deleterious BRCA mutation . - Determine response rate ( CR + PR ) treatment BMN 673 patient advance breast carcinoma deleterious BRCA mutation . - Determine response rate ( CR + PR ) treatment BMN 673 patient advance solid tumor ( breast ovarian ) deleterious BRCA mutation . Eligibility : - Adult patient document deleterious BRCA 1 2 mutation histologically confirm ovarian , primary peritoneal , breast , prostate , pancreas , gastric solid tumor whose disease progress follow least one standard therapy acceptable standard treatment option . - No major surgery , radiation , chemotherapy within 4 week prior study enrollment , recover toxicity prior therapy least eligibility level . - Age great equal 18 year age ; ECOG performance status less equal 2 - Adequate organ function . - Willingness undergo tumor biopsy . Study Design : - BMN 673 administer orally day 28-day cycle . - Dosing establish recommended Phase II dose 1000 g/day day 28 day . - We plan accrue total 12 evaluable patient per cohort total 36 patient . To allow patient evaluable , accrual ceiling 42 patient . - Tumor biopsy mandatory baseline ( pre-dose ) , approximately 3-6 hour post BMN 673 day 8 . An optional tumor biopsy may also collect time disease progression . SCHEMA - BMN 673 administer orally day 28-day cycle - Tumor biopsy perform baseline ( pre-treatment ) 3-6 hr post dose cycle 1 day 8 . An optional tumor biopsy may also collect time disease progression . Tumor biopsy evaluate PAR level , DNA damage response marker &gt; =H2AX , cleave caspase 3 , ERCC1 , pNbs1 , XPF , RAD51 , pT1989ATR , , indicator ATR/ATM activation , chk1 chk2 - Blood sample CTC analysis collect baseline ( pre-treatment ) , cycle 1 day 1 ( 3-6 hour post dose ) , cycle 1 day 8 ( 3-6 hour post dose ) , cycle 2 day 1 ( 3-6 hour post dose , plus/minus 3 day schedule conflict ) , day 1 every subsequent cycle drug administration ( day 1 every 3 cycle patient study 12 month ) , time disease progression . - Blood sample PK analysis collect cycle 1 day 1 pre-dose 0.5 , 1 , 2 , 3 , 4 , 6,8 , 24 hour post-dose , cycle 1 day 8 ( 3-6 hour post dose ) , cycle 2 day 1 predose 3-6 hour post dose .</detailed_description>
	<mesh_term>Talazoparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>INCLUSION CRITERIA : Adult patient document deleterious BRCA 1 2 mutation histologically confirm ovarian , primary peritoneal , breast , prostate , pancreas , gastric solid tumor whose disease progress follow least one standard therapy acceptable standard treatment option . Patients either platinumnaive receive platinumbased therapy least 6 month great prior time enrollment ; patient receive platinum part adjuvant therapy recurrent disease within 6 month complete adjuvant therapy . Patients metastatic disease must receive least one line standard care ( SOC ) treatment metastatic disease prior enrollment Age great equal 18 year age . ECOG performance status less equal 2 Life expectancy great 3 month . Patients must normal organ marrow function define : leukocyte great equal 3,000/mcL absolute neutrophil count great equal 1,500/mcL platelet great equal 100,000/mcL total bilirubin less equal 1.5 time institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) less equal 3 time institutional upper limit normal creatinine less equal 1.5 time institutional upper limit normal OR creatinine clearance great equal 60 mL/min/1.73 ( 2 ) patient creatinine level institutional normal . The effect BMN 673 develop human fetus unknown . For reason PARP inhibitor know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day complete study treatment . Should woman become pregnant suspect pregnant partner participate study , inform treat physician immediately . Men treat enrol protocol must also agree use adequate contraception prior study , duration study participation , 3 month completion BMN 673 administration . Patients must able swallow whole tablet capsule . Nasogastric Gtube administration allow . Any gastrointestinal disease would impair ability swallow , retain , absorb drug allow . Ability understand willingness sign write informed consent document . Patients HER2positive advance breast cancer ovarian cancer receive least two line systemic therapy advance set . EXCLUSION CRITERIA : Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . Patients prior treatment PARP inhibitor ineligible . Patients receive investigational agent . Patients know active brain metastasis carcinomatous meningitis exclude clinical trial . Patients whose brain metastatic disease status remain stable great equal 4 week follow treatment brain metastasis eligible participate discretion principal investigator . Eligibility subject receive medication substance potential affect activity pharmacokinetics BMN 673 determine follow review principal investigator . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study effect study drug develop fetus unknown . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction BMN 673 . In addition , patient increase risk lethal infection treat marrow suppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Patients require use coumarinderivative anticoagulant warfarin exclude . Low molecular weight heparin permit prophylactic therapeutic use . Lowdose warfarin ( less equal 1 mg/day ) permit . Women currently lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 27, 2016</verification_date>
	<keyword>DNA Damage</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>BRCA Mutations</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>